PARP1 and central nervous system cancer: Indeed, the combination of TMZ and PARP inhibition against gliomas (sometimes including irradiation) is being or has been tested in clinical trials (NCT03212742; NCT03749187; NCT03914742; NCT01514201; NCT00994071; NCT02152982).